Inhibition of related<scp>JAK</scp>/<scp>STAT</scp>pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm
Santiago Barrio, Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Enriqueta Albízua(Hospital Universitario HM Madrid), Florinda Gilsanz(Hospital Universitario HM Madrid), Alicia Arenas(Universidad de Sevilla), Carmen Burgaleta(Universidad de Alcalá), Rosa Ayala(Hospital Universitario 12 De Octubre), Miguel Gallardo(Spanish National Cancer Research Centre), Ana Jiménez Ubieto(Hospital Universitario 12 De Octubre), Daniel Rueda(Research Institute Hospital 12 de Octubre), Inmaculada Rapado(Wellcome Sanger Institute)
Cited by 24
Related Papers
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523